Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.61 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475229 | 1.00 | CTSV (0.61) | CTSVCTSLSRD5A1SRD5A2ELANE | |
| SCHEMBL12663538 | 0.86 | POLB (0.53) | CTSVCTSLSRD5A1SRD5A2POLB | |
| SCHEMBL17181447 | 0.86 | KDM4E (0.45) | CTSVCTSLALDH1A1IMPDH2KMT2A | |
| SCHEMBL1898553 | 0.85 | CTSV (0.55) | CTSVCTSLSRD5A1SRD5A2ELANE | |
| SCHEMBL372048 | 0.83 | IMPDH2 (0.58) | ALDH1A1IMPDH2KMT2AMEN1HPGD | |
| SCHEMBL15275124 | 0.82 | IMPDH2 (0.50) | CTSVCTSLALDH1A1IMPDH2KMT2A | |
| SCHEMBL7284981 | 0.82 | IMPDH2 (0.50) | ALDH1A1IMPDH2KMT2AMEN1HPGD | |
| SCHEMBL7290454 | 0.82 | IMPDH2 (0.50) | ALDH1A1IMPDH2KMT2AMEN1HPGD | |
| SCHEMBL1894604 | 0.82 | ALDH1A1 (0.45) | CTSVCTSLSRD5A1SRD5A2POLB | |
| SCHEMBL7294056 | 0.81 | IMPDH2 (0.49) | CTSVCTSLALDH1A1IMPDH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433124-B | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-115433124-A | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-115433124-B | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-115433124-B | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-115433124-A | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CTSV 1093/4885CTSL 655/4885SRD5A1 4594/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | CTSV 1093/4885CTSL 655/4885SRD5A1 4594/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | CTSV 97/4885CTSL 5/4885SRD5A1 2820/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | CTSV 1093/4885CTSL 655/4885SRD5A1 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.